Erlotinib Tablets IP 150mg
ERLOLIEVA 150 MG (Erlotinib Tablets IP 150mg) is a targeted anticancer medicine used in the treatment of certain types of lung cancer and pancreatic cancer. It contains Erlotinib Hydrochloride, a highly effective Epidermal Growth Factor Receptor (EGFR) inhibitor that helps slow down the growth and spread of cancer cells in the body. This medicine is commonly prescribed by oncologists as part of modern targeted cancer therapy protocols for patients with specific cancer types and genetic profiles.
Cancer develops when abnormal cells grow uncontrollably and spread to other parts of the body. In some cancers, proteins known as Epidermal Growth Factor Receptors (EGFR) play an important role in helping cancer cells survive, multiply, and spread. ERLOLIEVA 150 MG works by blocking these receptors, thereby interfering with cancer cell growth and reducing tumor progression.
Unlike traditional chemotherapy, Erlotinib is a targeted therapy that focuses on specific pathways involved in cancer development. This targeted approach helps improve treatment effectiveness in eligible patients while minimizing damage to healthy cells. As a result, Erlotinib has become an important treatment option in oncology care, especially for patients with EGFR-positive cancers.
ERLOLIEVA 150 MG is commonly prescribed for:
• Non-Small Cell Lung Cancer (NSCLC)
• EGFR Mutation-Positive Lung Cancer
• Advanced or Metastatic Lung Cancer
• Pancreatic Cancer (in combination with other treatments)
• Long-term targeted oncology treatment programs
This medicine may be used as a first-line treatment or after other cancer therapies depending on the patient's condition, treatment history, and medical requirements.
ERLOLIEVA 150 MG is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and consistent therapeutic performance. It is intended strictly for use under the supervision of qualified healthcare professionals experienced in oncology treatment.
Patients receiving Erlotinib therapy may require regular medical monitoring, blood tests, liver function assessments, and imaging studies during treatment. Proper monitoring helps evaluate treatment response and manage potential side effects effectively.
Due to its effectiveness in targeted oncology therapy, ERLOLIEVA 150 MG has become an important medicine in modern cancer care and personalized treatment programs.
View Details
Nintedanib Softgelatin Capsules 150mg
NINDALIEVA 150 MG (Nintedanib Softgelatin Capsules 150 mg) is a prescription medicine used for the treatment of Idiopathic Pulmonary Fibrosis (IPF), Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), and certain other chronic lung conditions as prescribed by healthcare professionals. It contains Nintedanib 150 mg, a tyrosine kinase inhibitor that helps slow the progression of lung fibrosis by targeting multiple pathways involved in tissue scarring and abnormal cell growth.
Idiopathic Pulmonary Fibrosis is a serious chronic lung disease characterized by progressive scarring of lung tissue. Over time, this scarring reduces the lungs' ability to transfer oxygen into the bloodstream, making breathing increasingly difficult. NINDALIEVA 150 MG helps slow the rate of lung function decline, supporting long-term respiratory health and improving disease management.
Nintedanib works by blocking specific growth factor receptors involved in the formation of fibrotic tissue. By inhibiting these pathways, the medicine helps reduce excessive scar tissue development in the lungs and may delay disease progression in eligible patients.
In addition to pulmonary fibrosis, Nintedanib is also used in selected patients with other progressive interstitial lung diseases and may be prescribed as part of comprehensive respiratory care programs.
NINDALIEVA 150 MG is commonly prescribed for:
• Idiopathic Pulmonary Fibrosis (IPF)
• Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
• Chronic Progressive Lung Fibrosis
• Long-Term Pulmonary Disease Management
• Specialist Respiratory Care Programs
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in respiratory medicine.
Patients receiving Nintedanib therapy may require regular monitoring of liver function, lung function, overall treatment response, and routine medical assessments. These evaluations help healthcare providers optimize treatment outcomes and identify potential side effects early.
Due to its effectiveness in slowing disease progression and supporting long-term respiratory care, NINDALIEVA 150 MG has become an important treatment option in modern pulmonary medicine.
View Details
Crizotinib Tablets 250mg
CRIZLIEVA 250 MG (Crizotinib Tablets 250 mg) is a prescription targeted anticancer medicine containing Crizotinib 250 mg, used for the treatment of specific types of advanced and metastatic cancers that carry certain genetic abnormalities. Crizotinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs) and is designed to block abnormal proteins that drive cancer cell growth, survival, and spread.
Cancer develops when cells acquire genetic mutations that allow them to multiply uncontrollably. In some patients with Non-Small Cell Lung Cancer (NSCLC) and other rare cancers, abnormal changes in genes such as ALK (Anaplastic Lymphoma Kinase), ROS1, or MET can stimulate continuous cancer cell growth. CRIZLIEVA 250 MG specifically targets these abnormal signaling pathways, helping slow disease progression and improve treatment outcomes.
Unlike traditional chemotherapy, which may affect both healthy and cancerous cells, Crizotinib is a targeted therapy that focuses on specific cancer-driving mutations. This targeted approach allows for more precise treatment and has become an important option in modern oncology.
CRIZLIEVA 250 MG is commonly prescribed for:
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
ROS1-Positive Non-Small Cell Lung Cancer
Advanced Lung Cancer
Metastatic Lung Cancer
MET-Positive Tumors (in selected patients)
Targeted Oncology Treatment Programs
Precision Cancer Therapy
Long-Term Cancer Management
Before starting treatment, doctors often perform specialized molecular testing to identify whether the patient's cancer carries the genetic alterations that make Crizotinib an appropriate treatment option.
Manufactured under stringent pharmaceutical quality standards, CRIZLIEVA 250 MG is designed to provide consistent quality, effectiveness, and patient safety.
Patients receiving Crizotinib therapy require regular medical monitoring, including blood tests, liver function assessments, vision evaluations, heart monitoring, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven clinical benefits and targeted mechanism of action, CRIZLIEVA 250 MG remains an important treatment option in modern precision oncology worldwide.
View Details
Afatinib Tablets IP 30mg
AFALIEVA 30 MG (Afatinib Tablets IP 30 mg) is a prescription targeted anticancer medicine containing Afatinib 30 mg, used primarily for the treatment of specific types of Non-Small Cell Lung Cancer (NSCLC) that carry certain Epidermal Growth Factor Receptor (EGFR) mutations. Afatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs) and works by blocking cancer-promoting signals that help tumors grow and spread.
Lung cancer remains one of the most commonly diagnosed cancers worldwide. In some patients, cancer cells contain abnormal EGFR mutations that continuously stimulate tumor growth. AFALIEVA 30 MG is specifically designed to target these mutations, helping slow disease progression and improve treatment outcomes.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Afatinib is a targeted therapy that focuses on specific molecular pathways involved in cancer development. This precision-based approach allows healthcare providers to personalize treatment according to the genetic profile of the tumor.
AFALIEVA 30 MG is commonly prescribed for:
EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Advanced Non-Small Cell Lung Cancer
Metastatic Lung Cancer
Locally Advanced Lung Cancer
Squamous Cell Carcinoma of the Lung (selected cases)
Targeted Oncology Treatment Programs
Precision Cancer Therapy
Long-Term Cancer Management
Before initiating treatment, oncologists generally recommend molecular testing to confirm the presence of EGFR mutations and determine whether Afatinib is an appropriate treatment option.
Afatinib works by irreversibly blocking multiple members of the ErbB family of receptors, including EGFR, HER2, and HER4. By inhibiting these pathways, it reduces cancer cell growth, limits tumor progression, and promotes cancer cell death.
Manufactured under strict pharmaceutical quality standards, AFALIEVA 30 MG is designed to provide consistent therapeutic performance, quality, and patient safety.
Patients receiving Afatinib therapy typically undergo regular monitoring, including liver function tests, kidney assessments, clinical evaluations, and treatment response assessments to ensure safe and effective therapy.
Due to its proven efficacy in EGFR-positive lung cancer, AFALIEVA 30 MG has become an important component of modern targeted cancer treatment strategies worldwide.
View Details
Afatinib Tablets IP 40mg
AFALIEVA 40 MG (Afatinib Tablets IP 40 mg) is a prescription targeted anticancer medication containing Afatinib 40 mg, a highly effective tyrosine kinase inhibitor (TKI) used in the treatment of specific types of Non-Small Cell Lung Cancer (NSCLC) associated with Epidermal Growth Factor Receptor (EGFR) mutations. Afatinib is designed to target and block abnormal proteins that drive cancer cell growth, multiplication, and spread throughout the body.
Lung cancer is among the most frequently diagnosed cancers worldwide, and advances in molecular diagnostics have made it possible to identify genetic mutations that can be specifically targeted with precision medicines. Patients whose tumors carry EGFR mutations often benefit from targeted therapies such as Afatinib, which are developed to attack cancer cells more selectively than traditional chemotherapy.
AFALIEVA 40 MG works by irreversibly inhibiting members of the ErbB receptor family, including EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4). These receptors are involved in signaling pathways that regulate cell growth and survival. When mutated, they can cause uncontrolled cancer cell proliferation. By blocking these signals, Afatinib helps slow tumor growth, reduce disease progression, and improve clinical outcomes.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, targeted therapies focus on specific cancer-driving mechanisms. This approach allows for more personalized treatment and has become a cornerstone of modern oncology.
AFALIEVA 40 MG is commonly prescribed for:
EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Advanced Non-Small Cell Lung Cancer
Metastatic Lung Cancer
Locally Advanced Lung Cancer
Recurrent Lung Cancer
Squamous Cell Carcinoma of the Lung (selected cases)
Precision Oncology Treatment Programs
Long-Term Targeted Cancer Therapy
Before treatment begins, patients generally undergo molecular testing to confirm the presence of EGFR mutations and determine eligibility for Afatinib therapy.
Manufactured under strict pharmaceutical quality standards, AFALIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Afatinib treatment usually require regular monitoring through clinical assessments, blood tests, liver function evaluations, and treatment response reviews to ensure optimal outcomes.
Due to its proven efficacy and targeted mechanism of action, AFALIEVA 40 MG is widely recognized as an important treatment option in modern lung cancer management.
View Details
Lenvatinib Capsules 10mg
LENVALIEVA 10 MG (Lenvatinib Capsules 10 mg) is a prescription targeted anticancer medicine containing Lenvatinib 10 mg, an advanced multi-kinase inhibitor used for the treatment of several types of cancer. It is commonly prescribed for patients with thyroid cancer, liver cancer, kidney cancer, and endometrial cancer, helping to slow tumor growth, delay disease progression, and improve treatment outcomes.
Lenvatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs). It works by blocking specific proteins involved in tumor growth and blood vessel formation. Cancer cells require a continuous blood supply to receive oxygen and nutrients needed for growth. LENVALIEVA 10 MG helps prevent the formation of new blood vessels that feed tumors, thereby limiting cancer progression.
Unlike conventional chemotherapy, which attacks rapidly dividing cells throughout the body, Lenvatinib specifically targets pathways involved in cancer growth and angiogenesis (blood vessel formation). This targeted approach has made it an important component of modern oncology treatment strategies.
LENVALIEVA 10 MG is commonly prescribed for:
Differentiated Thyroid Cancer (DTC)
Radioactive Iodine-Refractory Thyroid Cancer
Hepatocellular Carcinoma (Liver Cancer)
Advanced Renal Cell Carcinoma (Kidney Cancer)
Advanced Endometrial Cancer
Metastatic Solid Tumors (Selected Cases)
Targeted Oncology Treatment Programs
Long-Term Cancer Management
The medicine may be used alone or in combination with other anticancer therapies depending on the patient's diagnosis, disease stage, and treatment goals.
Lenvatinib has become a valuable treatment option because it targets multiple pathways involved in cancer progression, helping improve disease control in patients with advanced cancers.
Manufactured according to stringent pharmaceutical quality standards, LENVALIEVA 10 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenvatinib therapy require routine medical monitoring, including blood pressure assessments, liver function tests, kidney function evaluations, thyroid monitoring, and regular clinical examinations.
Due to its targeted mechanism and broad clinical applications, LENVALIEVA 10 MG plays an important role in modern cancer care worldwide.
View Details
Pemetrexed Injection IP 500mg
ALIMLIEVA 500 mg contains Pemetrexed, a chemotherapy (anticancer) drug classified as a multitargeted antifolate antimetabolite. It inhibits key enzymes involved in purine and pyrimidine synthesis, leading to inhibition of DNA and RNA synthesis and cancer cell death. It is mainly used in non-squamous lung cancers.
View Details
Pemetrexed Injection IP 100mg
ALIMLIEVA 100 mg contains Pemetrexed, a chemotherapy (anticancer) medicine classified as a multitargeted antifolate. It inhibits several enzymes involved in DNA and RNA synthesis, leading to suppression of cancer cell growth. It is mainly used in non-squamous lung cancers.
View Details
